620 related articles for article (PubMed ID: 20127825)
1. Drug-polymer solubility and miscibility: Stability consideration and practical challenges in amorphous solid dispersion development.
Qian F; Huang J; Hussain MA
J Pharm Sci; 2010 Jul; 99(7):2941-7. PubMed ID: 20127825
[TBL] [Abstract][Full Text] [Related]
2. Classification of solid dispersions: correlation to (i) stability and solubility (ii) preparation and characterization techniques.
Meng F; Gala U; Chauhan H
Drug Dev Ind Pharm; 2015; 41(9):1401-15. PubMed ID: 25853292
[TBL] [Abstract][Full Text] [Related]
3. Amorphous stabilization and dissolution enhancement of amorphous ternary solid dispersions: combination of polymers showing drug-polymer interaction for synergistic effects.
Prasad D; Chauhan H; Atef E
J Pharm Sci; 2014 Nov; 103(11):3511-3523. PubMed ID: 25196860
[TBL] [Abstract][Full Text] [Related]
4. Analytical and Computational Methods for the Determination of Drug-Polymer Solubility and Miscibility.
Thakore SD; Akhtar J; Jain R; Paudel A; Bansal AK
Mol Pharm; 2021 Aug; 18(8):2835-2866. PubMed ID: 34041914
[TBL] [Abstract][Full Text] [Related]
5. Polymeric Amorphous Solid Dispersions: A Review of Amorphization, Crystallization, Stabilization, Solid-State Characterization, and Aqueous Solubilization of Biopharmaceutical Classification System Class II Drugs.
Baghel S; Cathcart H; O'Reilly NJ
J Pharm Sci; 2016 Sep; 105(9):2527-2544. PubMed ID: 26886314
[TBL] [Abstract][Full Text] [Related]
6. Emerging trends in the stabilization of amorphous drugs.
Laitinen R; Löbmann K; Strachan CJ; Grohganz H; Rades T
Int J Pharm; 2013 Aug; 453(1):65-79. PubMed ID: 22569230
[TBL] [Abstract][Full Text] [Related]
7. Impact of polymer type on bioperformance and physical stability of hot melt extruded formulations of a poorly water soluble drug.
Mitra A; Li L; Marsac P; Marks B; Liu Z; Brown C
Int J Pharm; 2016 May; 505(1-2):107-14. PubMed ID: 27012984
[TBL] [Abstract][Full Text] [Related]
8. Solubility advantage from amorphous etoricoxib solid dispersions.
Dani P; Puri V; Bansal AK
Drug Dev Ind Pharm; 2014 Jan; 40(1):92-101. PubMed ID: 23301771
[TBL] [Abstract][Full Text] [Related]
9. Molecular implications of drug-polymer solubility in understanding the destabilization of solid dispersions by milling.
Yang Z; Nollenberger K; Albers J; Qi S
Mol Pharm; 2014 Jul; 11(7):2453-65. PubMed ID: 24897345
[TBL] [Abstract][Full Text] [Related]
10. Refining stability and dissolution rate of amorphous drug formulations.
Grohganz H; Priemel PA; Löbmann K; Nielsen LH; Laitinen R; Mullertz A; Van den Mooter G; Rades T
Expert Opin Drug Deliv; 2014 Jun; 11(6):977-89. PubMed ID: 24754747
[TBL] [Abstract][Full Text] [Related]
11. Qualitative and quantitative methods to determine miscibility in amorphous drug-polymer systems.
Meng F; Dave V; Chauhan H
Eur J Pharm Sci; 2015 Sep; 77():106-11. PubMed ID: 26006307
[TBL] [Abstract][Full Text] [Related]
12. Using Flory-Huggins phase diagrams as a pre-formulation tool for the production of amorphous solid dispersions: a comparison between hot-melt extrusion and spray drying.
Tian Y; Caron V; Jones DS; Healy AM; Andrews GP
J Pharm Pharmacol; 2014 Feb; 66(2):256-74. PubMed ID: 24192445
[TBL] [Abstract][Full Text] [Related]
13. Predicting Solubility/Miscibility in Amorphous Dispersions: It Is Time to Move Beyond Regular Solution Theories.
Anderson BD
J Pharm Sci; 2018 Jan; 107(1):24-33. PubMed ID: 29031973
[TBL] [Abstract][Full Text] [Related]
14. Coamorphous Active Pharmaceutical Ingredient-Small Molecule Mixtures: Considerations in the Choice of Coformers for Enhancing Dissolution and Oral Bioavailability.
Newman A; Reutzel-Edens SM; Zografi G
J Pharm Sci; 2018 Jan; 107(1):5-17. PubMed ID: 28989014
[TBL] [Abstract][Full Text] [Related]
15. An investigation into the role of polymeric carriers on crystal growth within amorphous solid dispersion systems.
Tian Y; Jones DS; Andrews GP
Mol Pharm; 2015 Apr; 12(4):1180-92. PubMed ID: 25692314
[TBL] [Abstract][Full Text] [Related]
16. Construction of drug-polymer thermodynamic phase diagrams using Flory-Huggins interaction theory: identifying the relevance of temperature and drug weight fraction to phase separation within solid dispersions.
Tian Y; Booth J; Meehan E; Jones DS; Li S; Andrews GP
Mol Pharm; 2013 Jan; 10(1):236-48. PubMed ID: 23110477
[TBL] [Abstract][Full Text] [Related]
17. Effects of Polymers on the Drug Solubility and Dissolution Enhancement of Poorly Water-Soluble Rivaroxaban.
Choi MJ; Woo MR; Choi HG; Jin SG
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012748
[TBL] [Abstract][Full Text] [Related]
18. Estimation of drug-polymer miscibility and solubility in amorphous solid dispersions using experimentally determined interaction parameters.
Marsac PJ; Li T; Taylor LS
Pharm Res; 2009 Jan; 26(1):139-51. PubMed ID: 18779927
[TBL] [Abstract][Full Text] [Related]
19. The effect of drug and EUDRAGIT® S 100 miscibility in solid dispersions on the drug and polymer dissolution rate.
Higashi K; Hayashi H; Yamamoto K; Moribe K
Int J Pharm; 2015 Oct; 494(1):9-16. PubMed ID: 26253374
[TBL] [Abstract][Full Text] [Related]
20. Physical Stability of Amorphous Solid Dispersions: a Physicochemical Perspective with Thermodynamic, Kinetic and Environmental Aspects.
Lin X; Hu Y; Liu L; Su L; Li N; Yu J; Tang B; Yang Z
Pharm Res; 2018 Apr; 35(6):125. PubMed ID: 29687226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
